Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes

Morten Møller Poulsen; Karen Fjeldborg; Marie Juul Ornstrup; Thomas Nordstrøm Kjær; Mark Klitgaard Nøhr; Steen Bønløkke Pedersen

doi:10.1016/j.bbadis.2014.12.024

Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes

Morten Møller Poulsen, Karen Fjeldborg, Marie Juul Ornstrup, Thomas Nordstrøm Kjær, Mark Klitgaard Nøhr, Steen Bønløkke Pedersen

Department of Clinical Medicine - Department of Endocrinology and Internal Medicine

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

117 Citations (Scopus)

Abstract

Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

Original language	English
Journal	B B A - Molecular Basis of Disease
Pages (from-to)	1124-1136
ISSN	0925-4439
DOIs	https://doi.org/10.1016/j.bbadis.2014.12.024
Publication status	Published - 9 Jan 2015

Access to Document

10.1016/j.bbadis.2014.12.024

Cite this

@article{ca40ad74641140dea543a6e62aabb6c1,

title = "Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes",

abstract = "Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.",

author = "Poulsen, {Morten M{\o}ller} and Karen Fjeldborg and Ornstrup, {Marie Juul} and Kj{\ae}r, {Thomas Nordstr{\o}m} and N{\o}hr, {Mark Klitgaard} and Pedersen, {Steen B{\o}nl{\o}kke}",

year = "2015",

month = jan,

day = "9",

doi = "10.1016/j.bbadis.2014.12.024",

language = "English",

pages = "1124--1136",

journal = "B B A - Molecular Basis of Disease",

issn = "0925-4439",

publisher = "Elsevier B.V.",

}

Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. / Poulsen, Morten Møller; Fjeldborg, Karen; Ornstrup, Marie Juul et al.
In: B B A - Molecular Basis of Disease, 09.01.2015, p. 1124-1136.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Resveratrol and inflammation

T2 - Challenges in translating pre-clinical findings to improved patient outcomes

AU - Poulsen, Morten Møller

AU - Fjeldborg, Karen

AU - Ornstrup, Marie Juul

AU - Kjær, Thomas Nordstrøm

AU - Nøhr, Mark Klitgaard

AU - Pedersen, Steen Bønløkke

PY - 2015/1/9

Y1 - 2015/1/9

N2 - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

AB - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

U2 - 10.1016/j.bbadis.2014.12.024

DO - 10.1016/j.bbadis.2014.12.024

M3 - Journal article

C2 - 25583116

SN - 0925-4439

SP - 1124

EP - 1136

JO - B B A - Molecular Basis of Disease

JF - B B A - Molecular Basis of Disease

ER -

Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes

Abstract

Access to Document

Fingerprint

Cite this